Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

November 29, 2018

Primary Completion Date

July 14, 2025

Study Completion Date

October 3, 2026

Conditions
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
Interventions
DRUG

Atezolizumab

Given IV

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood

DRUG

Cobimetinib

Given PO

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (18)

10065

NYP/Weill Cornell Medical Center, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

20007

MedStar Georgetown University Hospital, Washington D.C.

22908

University of Virginia Cancer Center, Charlottesville

27012

Wake Forest University at Clemmons, Clemmons

27157

Wake Forest University Health Sciences, Winston-Salem

27262

Hayworth Cancer Center, High Point

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

33612

Moffitt Cancer Center, Tampa

35233

University of Alabama at Birmingham Cancer Center, Birmingham

43210

Ohio State University Comprehensive Cancer Center, Columbus

48201

Wayne State University/Karmanos Cancer Institute, Detroit

73104

University of Oklahoma Health Sciences Center, Oklahoma City

92093

UC San Diego Moores Cancer Center, La Jolla

03756

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03600701 - Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter